RenovoRx RNXT 深 滬
已收盤 12-24 16:00:00 美东时间
0.8955
-0.014
-1.59%
華盛通- 最 高0.9299
- 今 開0.92
- 成交量 12.67万股
- 最 低 0.8901
- 昨 收 0.91
- 總市值 3281.64万
- 52周最高 1.6899
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.7006
- 委 比 -1.14%
- 總股本 3664.59万
- 歷史最高 16.74
- 量 比 0.82
- 振 幅 4.37%
- 歷史最低 0.5306
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
【答案】 RenovoRx, Inc. announced that its abstract regarding the TAMP™ Therapy Platform and RenovoCath® device has been accepted for presentation at the 2026 ASCO GI Symposium. The study compares intra-arterial gemcitabine delivery to standard intravenous chemotherapy for locally advanced pancreatic cancer, with findings supporting reduced systemic drug levels and potential for fewer side effects. The presentation will occur on January 9, 2026, in S...
12-11 13:30
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
RenovoRx, Inc. announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9, 2025. The presentation will cover commercial efforts, market traction of RenovoCath, clinical advancements, and updates on the Phase III TIGeR-PaC trial for pancreatic cancer treatment. The company reported year-to-date revenue of approximately $900,000 as of September 2025. A replay will be available...
12-01 13:30
RenovoRx Enters Capital on Demand Sales Agreement
RenovoRx ( ($RNXT) ) has provided an update. On November 14, 2025, RenovoRx, In...
11-15 06:29
RenovoRx Expands Reach with RenovoCath Approval
RenovoRx ( ($RNXT) ) has issued an announcement. RenovoRx reported its third-qu...
11-14 05:54
RenovoRx Q3 EPS $(0.08), Inline, Sales $266.000K Miss $405.333K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company
11-14 05:11
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
RenovoRx reported $266,000 in revenue for Q3 2025, driven by RenovoCath sales, with $10 million in cash and a net loss of $2.9 million. The company expanded its customer base to 14 cancer centers and engaged 24 centers for quotes, highlighting clinical adoption growth. Progress continues on the Phase III TIGeR-PaC trial, with enrollment expected to complete in early 2026 and final data in 2027. The launch of a post-marketing registry study aims t...
11-13 21:05
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a life-sciences company, announced that CEO Shaun Bagai will present at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20, 2025. He will discuss the commercial progress of its FDA-cleared RenovoCath drug-delivery device and updates on its Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC). The Company also launched a post-marketing ...
11-04 13:30
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
<p><p align="justify">MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc., a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath® drug-delivery device, announced it will host its third quarter 2025 financial results conference call on November 13, 2025, at 4:30 p.m. ET. The call will discuss recent developments in RenovoCath® commercialization, the Phase III TIGeR-PaC trial fo...
10-27 12:30
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
